MedPath

Efficacy and Safety of Tiotropium and Salmeterol in Moderate Persistent Asthma Patients Homozygous for B16-Arg/Arg

Phase 2
Completed
Conditions
Asthma
Registration Number
NCT00350207
Lead Sponsor
Boehringer Ingelheim
Brief Summary

This is a 16 week multicentre, multinational, randomised, double-blind, double-dummy, placebo-controlled, parallel group study to evaluate the long-term efficacy and safety of tiotropium compared to salmeterol in moderate persistent asthmatic (GINA step 3) patients homozygous for arginine at the 16th amino acid position of the beta-adrenergic receptor (ADRB2). Following an initial 4-week run-in period on salmeterol MDI patients will be randomised into the 16 week double-blind treatment period in which they receive either tiotropium once daily administered from the Respimat inhaler or salmeterol twice daily administered from the hydrofluoro-alkane Metered Dose Inhaler (MDI), or placebo twice daily. After the 16 week treatment period all patients will receive salmeterol MDI twice daily for four weeks.

The patients perform daily morning and evening peak flow (PEF) and Forced Expiratory Volume in the First Second (FEV1) measurements with an electronic peak flow meter throughout the study. Daily data on asthma control and use of rescue medication are recorded using an electronic diary included in the electronic peak flow meter. On study visits the Mini-Asthma Quality of Life Questionnaire (Elizabeth Juniper) is administered, pulse and blood pressure and pre-dose pulmonary function testing (FEV1 and Forced Vital Capacity) are performed.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
388
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Change in Mean Weekly Morning Peak Expiratory Flow From Baseline to the End of the Trialbaseline and after 16 weeks of treatment

Change from baseline in mean weekly morning peak expiratory flow at 16 weeks. Baseline is defined as the last week prior to the randomisation visit

Secondary Outcome Measures
NameTimeMethod
Mean Weekly Score for Asthma Control Diary Question "How Were Your Asthma Symptoms During the Day" at Week 16After 16 weeks of treatment

Unit on a scale 1-5. 1: No asthma symptoms, 2: Mild asthma symptoms, 3: Moderate asthma symptoms, 4: Severe asthma symptoms, 5: Very severe asthma symptoms. 1 is the best value

Mean Weekly Morning Peak Expiratory Flow at Week 8After 8 weeks of treatment

Mean weekly morning peak expiratory flow at week 8, pre-dose

Mean Weekly Morning Peak Expiratory Flow at Week 12After 12 weeks of treatment

Mean weekly morning peak expiratory flow at week 12, pre-dose

Mean Weekly Morning Peak Expiratory Flow at Week 16After 16 weeks of treatment

Mean weekly morning peak expiratory flow at week 16, pre-dose

Mean Weekly Evening Peak Expiratory Flow at Week 12After 12 weeks of treatment

Mean weekly evening peak expiratory flow at week 12, pre-dose

Mean Weekly Evening Peak Expiratory Flow at Week 16After 16 weeks of treatment

Mean weekly evening peak expiratory flow at week 16, pre-dose

Mean Weekly Morning Forced Expiratory Volume in 1 Second at Week 4After 4 weeks of treatment

Mean weekly morning forced expiratory volume in 1 second at week 4, pre-dose

Mean Weekly Morning Forced Expiratory Volume in 1 Second at Week 8After 8 weeks of treatment

Mean weekly morning forced expiratory volume in 1 second at week 8, pre-dose

Mean Weekly Morning Forced Expiratory Volume in 1 Second at Week 12After 12 weeks of treatment

Mean weekly morning forced expiratory volume in 1 second at week 12, pre-dose

Mean Weekly Morning Forced Expiratory Volume in 1 Second at Week 16After 16 weeks of treatment

Mean weekly morning forced expiratory volume in 1 second at week 16, pre-dose

Mean Weekly Evening Forced Expiratory Volume in 1 Second at Week 4After 4 weeks of treatment

Mean weekly evening forced expiratory volume in 1 second at week 4, pre-dose

Mean Weekly Evening Forced Expiratory Volume in 1 Second at Week 8After 8 weeks of treatment

Mean weekly evening forced expiratory volume in 1 second at week 8, pre-dose

Mean Weekly Evening Forced Expiratory Volume in 1 Second at Week 12After 12 weeks of treatment

Mean weekly evening forced expiratory volume in 1 second at week 12, pre-dose

Mean Weekly Evening Forced Expiratory Volume in 1 Second at Week 16After 16 weeks of treatment

Mean weekly evening forced expiratory volume in 1 second at week 16, pre-dose

Mean Weekly Score for Asthma Control Diary Question "Did You Wake up During the Night Due to Asthma" at Week 4After 4 weeks of treatment

Unit on a scale 1-5. 1: Did not wake up, 2: Woke up once, 3: Woke up 2-5 times, 4: Woke up more than 5 times, 5: Was awake all night. 1 is the best value

Mean Weekly Score for Asthma Control Diary Question "Did You Wake up During the Night Due to Asthma" at Week 8After 8 weeks of treatment

Unit on a scale 1-5. 1: Did not wake up, 2: Woke up once, 3: Woke up 2-5 times, 4: Woke up more than 5 times, 5: Was awake all night. 1 is the best value

Mean Weekly Score for Asthma Control Diary Question "Did You Wake up During the Night Due to Asthma" at Week 12After 12 weeks of treatment

Unit on a scale 1-5. 1: Did not wake up, 2: Woke up once, 3: Woke up 2-5 times, 4: Woke up more than 5 times, 5: Was awake all night. 1 is the best value

Mean Weekly Score for Asthma Control Diary Question "Did You Wake up During the Night Due to Asthma" at Week 16After 16 weeks of treatment

Unit on a scale 1-5. 1: Did not wake up, 2: Woke up once, 3: Woke up 2-5 times, 4: Woke up more than 5 times, 5: Was awake all night. 1 is the best value

Mean Weekly Score for Asthma Control Diary Question "How Were Your Asthma Symptoms in the Morning" at Week 4After 4 weeks of treatment

Unit on a scale 1-5. 1: No asthma symptoms, 2: Mild asthma symptoms, 3: Moderate asthma symptoms, 4: Severe asthma symptoms, 5: Very severe asthma symptoms. 1 is the best value

Mean Weekly Score for Asthma Control Diary Question "How Were Your Asthma Symptoms This Morning" at Week 8After 8 weeks of treatment

Unit on a scale 1-5. 1: No asthma symptoms, 2: Mild asthma symptoms, 3: Moderate asthma symptoms, 4: Severe asthma symptoms, 5: Very severe asthma symptoms. 1 is the best value

Mean Weekly Score for Asthma Control Diary Question "How Were Your Asthma Symptoms This Morning" at Week 12After 12 weeks of treatment

Unit on a scale 1-5. 1: No asthma symptoms, 2: Mild asthma symptoms, 3: Moderate asthma symptoms, 4: Severe asthma symptoms, 5: Very severe asthma symptoms. 1 is the best value

Mean Weekly Score for Asthma Control Diary Question "How Were Your Asthma Symptoms This Morning" at Week 16After 16 weeks of treatment

Unit on a scale 1-5. 1: No asthma symptoms, 2: Mild asthma symptoms, 3: Moderate asthma symptoms, 4: Severe asthma symptoms, 5: Very severe asthma symptoms. 1 is the best value

Mean Weekly Score for Asthma Control Diary Question "How Were Your Asthma Symptoms During the Day" at Week 4After 4 weeks of treatment

Unit on a scale 1-5. 1: No asthma symptoms, 2: Mild asthma symptoms, 3: Moderate asthma symptoms, 4: Severe asthma symptoms, 5: Very severe asthma symptoms. 1 is the best value

Mean Weekly Score for Asthma Control Diary Question "How Were Your Asthma Symptoms During the Day" at Week 8After 8 weeks of treatment

Unit on a scale 1-5. 1: No asthma symptoms, 2: Mild asthma symptoms, 3: Moderate asthma symptoms, 4: Severe asthma symptoms, 5: Very severe asthma symptoms. 1 is the best value

Mean Weekly Score for Asthma Control Diary Question "How Were Your Asthma Symptoms During the Day" at Week 12After 12 weeks of treatment

Unit on a scale 1-5. 1: No asthma symptoms, 2: Mild asthma symptoms, 3: Moderate asthma symptoms, 4: Severe asthma symptoms, 5: Very severe asthma symptoms. 1 is the best value

Mean Weekly Score for Asthma Control Diary Question "How Limited Were You in Your Activities Today Because of Your Asthma" at Week 4After 4 weeks of treatment

Unit on a scale 1-5. 1: Not limited at all, 2: A little limited, 3: Moderately limited, 4: Severely limited, 5: Totally limited. 1 is the best value

Mean Weekly Score for Asthma Control Diary Question "How Limited Were You in Your Activities Today Because of Your Asthma" at Week 8After 8 weeks of treatment

Unit on a scale 1-5. 1: Not limited at all, 2: A little limited, 3: Moderately limited, 4: Severely limited, 5: Totally limited. 1 is the best value

Mean Weekly Score for Asthma Control Diary Question "How Limited Were You in Your Activities Today Because of Your Asthma" at Week 12After 12 weeks of treatment

Unit on a scale 1-5. 1: Not limited at all, 2: A little limited, 3: Moderately limited, 4: Severely limited, 5: Totally limited. 1 is the best value

Mean Weekly Score for Asthma Control Diary Question "How Limited Were You in Your Activities Today Because of Your Asthma" at Week 16After 16 weeks of treatment

Unit on a scale 1-5. 1: Not limited at all, 2: A little limited, 3: Moderately limited, 4: Severely limited, 5: Totally limited. 1 is the best value

Mean Weekly Score for Asthma Control Diary Question "How Much Shortness of Breath Did You Experience During the Day" at Week 4After 4 weeks of treatment

Unit on a scale 1-5. 1: None, 2: A very little, 3: A moderate amount, 4: Quite a lot, 5: A very great deal. 1 is the best value

Mean Weekly Score for Asthma Control Diary Question "How Much Shortness of Breath Did You Experience During the Day" at Week 8After 8 weeks of treatment

Unit on a scale 1-5. 1: None, 2: A very little, 3: A moderate amount, 4: Quite a lot, 5: A very great deal. 1 is the best value

Mean Weekly Score for Asthma Control Diary Question "How Much Shortness of Breath Did You Experience During the Day" at Week 12After 12 weeks of treatment

Unit on a scale 1-5. 1: None, 2: A very little, 3: A moderate amount, 4: Quite a lot, 5: A very great deal. 1 is the best value

Mean Weekly Score for Asthma Control Diary Question "How Much Shortness of Breath Did You Experience During the Day" at Week 16After 16 weeks of treatment

Unit on a scale 1-5. 1: None, 2: A very little, 3: A moderate amount, 4: Quite a lot, 5: A very great deal. 1 is the best value

Mean Weekly Score for Asthma Control Diary Question "Did You Experience Wheeze or Cough During the Day" at Week 4After 4 weeks of treatment

Unit on a scale 1-5. 1: Not at all, 2: A little of the time, 3: A moderate amount of the time, 4: Most of the time, 5: All the time. 1 is the best value

Mean Weekly Score for Asthma Control Diary Question "Did You Experience Wheeze or Cough During the Day" at Week 8After 8 weeks of treatment

Unit on a scale 1-5. 1: Not at all, 2: A little of the time, 3: A moderate amount of the time, 4: Most of the time, 5: All the time. 1 is the best value

Mean Weekly Score for Asthma Control Diary Question "Did You Experience Wheeze or Cough During the Day" at Week 12After 12 weeks of treatment

Unit on a scale 1-5. 1: Not at all, 2: A little of the time, 3: A moderate amount of the time, 4: Most of the time, 5: All the time. 1 is the best value

Mean Weekly Score for Asthma Control Diary Question "Did You Experience Wheeze or Cough During the Day" at Week 16After 16 weeks of treatment

Unit on a scale 1-5. 1: Not at all, 2: A little of the time, 3: A moderate amount of the time, 4: Most of the time, 5: All the time. 1 is the best value

Morning Pre-dose Forced Expiratory Volume in 1 Second as Measured by Spirometry at Visit 3After 6 weeks of treatment

Morning pre-dose forced expiratory volume in 1 second as measured by spirometry after 6 weeks of treatment

Morning Pre-dose Forced Expiratory Volume in 1 Second as Measured by Spirometry at Visit 4After 12 weeks of treatment

Morning pre-dose forced expiratory volume in 1 second as measured by spirometry after 12 weeks of treatment

Morning Pre-dose Forced Expiratory Volume in 1 Second as Measured by Spirometry at Visit 5After 16 weeks of treatment

Morning pre-dose forced expiratory volume in 1 second as measured by spirometry after 16 weeks od treatment

Morning Pre-dose Forced Vital Capacity as Measured by Spirometry at Visit 5After 16 weeks of treatment

Morning pre-dose forced vital capacity as measured by spirometry after 16 weeks of treatment

Morning Pre-dose Forced Vital Capacity as Measured by Spirometry at Visit 3After 6 weeks of treatment

Morning pre-dose forced vital capacity as measured by spirometry after 6 weeks of treatment

Morning Pre-dose Forced Vital Capacity as Measured by Spirometry at Visit 4After 12 weeks of treatment

Morning pre-dose forced vital capacity as measured by spirometry after 12 weeks of treatment

Systolic Blood Pressure in Conjunction With Spirometry at Visit 5After 16 weeks of treatment

Systolic blood pressure collected in conjunction with spirometry at 16 weeks

Mini-Asthma Quality of Life Questionnaire (Mini-AQLQ) Overall Score at Visit 3After 6 weeks of treatment

Mean of the responses to 15 questions from 4 domains: Symptoms (1), Activity Limitations (2), Emotional Function (3), Environmental Stimuli (4). Unit on a scale 1-7. For domain (2): 1: totally limited, 2: extremely limited, 3: very limited, 4: moderate limitation, 5: some limitation, 6: a little limitation, 7: not at all limited. For other domains: 1: all of the time, 2: most of the time, 3: a good bit of the time, 4: some of the time, 5: a little of the time, 6: hardly any of the time, 7: none of the time. 7 is the best value

Mini-AQLQ Overall Score at Visit 4After 12 weeks of treatment

Mean of the responses to 15 questions from 4 domains: Symptoms (1), Activity Limitations (2), Emotional Function (3), Environmental Stimuli (4). Unit on a scale 1-7. For domain (2): 1: totally limited, 2: extremely limited, 3: very limited, 4: moderate limitation, 5: some limitation, 6: a little limitation, 7: not at all limited. For other domains: 1: all of the time, 2: most of the time, 3: a good bit of the time, 4: some of the time, 5: a little of the time, 6: hardly any of the time, 7: none of the time. 7 is the best value

Systolic Blood Pressure in Conjunction With Spirometry at Visit 3After 6 weeks of treatment

Systolic blood pressure collected in conjunction with spirometry at 6 weeks

Systolic Blood Pressure in Conjunction With Spirometry at Visit 4After 12 weeks of treatment

Systolic blood pressure collected in conjunction with spirometry at 12 weeks

Pulse Rate in Conjunction With Spirometry at Visit 3After 6 weeks of treatment

Pulse rate collected in conjunction with spirometry at 6 weeks

Mean PEF Variability at Week 8After 8 weeks of treatment

PEF (Peak expiratory flow) variability is defined as the difference between the highest morning PEF value and the highest evening PEF value of one day divided by the arithmetic mean of these two PEF values and multiplied by 100%

Mean PEF Variability at Week 12After 12 weeks of treatment

PEF (Peak expiratory flow) variability is defined as the difference between the highest morning PEF value and the highest evening PEF value of one day divided by the arithmetic mean of these two PEF values and multiplied by 100%

Mini-AQLQ Overall Score at Visit 5After 16 weeks of treatment

Mean of the responses to 15 questions from 4 domains: Symptoms (1), Activity Limitations (2), Emotional Function (3), Environmental Stimuli (4). Unit on a scale 1-7. For domain (2): 1: totally limited, 2: extremely limited, 3: very limited, 4: moderate limitation, 5: some limitation, 6: a little limitation, 7: not at all limited. For other domains: 1: all of the time, 2: most of the time, 3: a good bit of the time, 4: some of the time, 5: a little of the time, 6: hardly any of the time, 7: none of the time. 7 is the best value

Diastolic Blood Pressure in Conjunction With Spirometry at Visit 5After 16 weeks of treatment

Diastolic blood pressure collected in conjunction with spirometry at 16 weeks

Pulse Rate in Conjunction With Spirometry at Visit 4After 12 weeks of treatment

Pulse rate collected in conjunction with spirometry at 12 weeks

Pulse Rate in Conjunction With Spirometry at Visit 5After 16 weeks of treatment

Pulse rate collected in conjunction with spirometry at 16 weeks

Mean PEF Variability at Week 4After 4 weeks of treatment

PEF (Peak expiratory flow) variability is defined as the difference between the highest morning PEF value and the highest evening PEF value of one day divided by the arithmetic mean of these two PEF values and multiplied by 100%

Mean PEF Variability at Week 16After 16 weeks of treatment

PEF (Peak expiratory flow) variability is defined as the difference between the highest morning PEF value and the highest evening PEF value of one day divided by the arithmetic mean of these two PEF values and multiplied by 100%

Diastolic Blood Pressure in Conjunction With Spirometry at Visit 3After 6 weeks of treatment

Diastolic blood pressure collected in conjunction with spirometry at 6 weeks

Diastolic Blood Pressure in Conjunction With Spirometry at Visit 4After 12 weeks of treatment

Diastolic blood pressure collected in conjunction with spirometry at 12 weeks

Mean Weekly Morning Peak Expiratory Flow at Week 4After 4 weeks of treatment

Mean weekly morning peak expiratory flow at week 4, pre-dose

Mean Weekly Evening Peak Expiratory Flow at Week 4After 4 weeks of treatment

Mean weekly evening peak expiratory flow at week 4, pre-dose

Mean Weekly Evening Peak Expiratory Flow at Week 8After 8 weeks of treatment

Mean weekly evening peak expiratory flow at week 8, pre-dose

Trial Locations

Locations (109)

205.342.43002 Boehringer Ingelheim Investigational Site

🇦🇹

Graz, Austria

205.342.43004 Boehringer Ingelheim Investigational Site

🇦🇹

Trofaiach, Austria

205.342.43003 Boehringer Ingelheim Investigational Site

🇦🇹

Wels, Austria

205.342.43001 Boehringer Ingelheim Investigational Site

🇦🇹

Wien, Austria

205.342.43005 Boehringer Ingelheim Investigational Site

🇦🇹

Wien, Austria

205.342.43006 Boehringer Ingelheim Investigational Site

🇦🇹

Wien, Austria

205.342.43007 Boehringer Ingelheim Investigational Site

🇦🇹

Wien, Austria

205.342.32010 Boehringer Ingelheim Investigational Site

🇧🇪

Anderlecht, Belgium

205.342.32005 Boehringer Ingelheim Investigational Site

🇧🇪

Angleur, Belgium

205.342.32002 Boehringer Ingelheim Investigational Site

🇧🇪

Brussel, Belgium

Scroll for more (99 remaining)
205.342.43002 Boehringer Ingelheim Investigational Site
🇦🇹Graz, Austria

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.